Associated Papers
A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
Unseld M et al.
International Journal of Cancer, 2021
32949150 (PubMed )
Supplement: IJC-148-1452-s003.xlsx › Table_S3
Select a paper to view details